Novo Nordisk CEO says experimental weight loss pill could become a best-in-class drug

Novo Nordisk’s CEO stated that the company’s experimental weight loss drug, amycretin, could be a leading treatment for obesity. Novo Nordisk is working on developing new treatments for obesity following the success of their drug Wegovy. Recent trial data on amycretin has impressed investors, with patients on the pill losing about 13.1% of their weight after 12 weeks. This surpasses the weight loss seen in patients taking Wegovy. Novo Nordisk believes that offering weight loss pills in addition to injections will cater to the different preferences of patients. A midstage trial on amycretin is scheduled to begin later this year.